CTMX · CytomX Therapeutics Inc
United States · RS rating 7 · As of 2026-10-14
| Price | 2.23 USD |
|---|---|
| 1-day change | -4.1% |
| RS rating (overall / 1M / 3M / 12M) | 7 / 14 / 8 / 19 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 24 / 15 / 23 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +10.0% |
| Sales growth Q/Q | -88.9% |
| Distance from 52-week high | +67.0% |
| Market cap (USD) | $962.0M |